Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
COVID-19
COVID-19 Update
Evaluate Vantage COVID-19 Report
COVID-19 Stories from Evaluate Vantage
Evaluate’s Business Continuity Plan
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Evaluate Custom Solutions
Evaluate Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Evaluate Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Threshold Pharmaceuticals
January 24, 2017
Asco-GI – Pancreatic cancer field awaits sparse data
September 30, 2016
Snippet roundup: Wins for Amgen, cuts for Novo and confusion over Cabometyx
June 10, 2016
Asco event analyser – 2016’s winners and losers
March 17, 2016
Revisiting a predictor of failure in the post-Celator world
February 05, 2016
Pancreatic cancer 2016: this time it’s (getting) personal
December 08, 2015
Sarcoma field digests evofosfamide failure
December 03, 2015
Event – Threshold hopes to buck the F-R rule
June 03, 2015
Asco Event Analyzer – 2015’s winners and losers
May 13, 2015
HyperAcute Pancreas will go to the wire
September 19, 2014
An independent Bayer is no blueprint for German Merck
December 12, 2013
ASH Event Analyzer – Post-meeting selloff belies overall bullish trend
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
February 11, 2021
Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review
December 10, 2020
Evaluate Vantage 2021 Preview
Editor's Picks
March 22, 2021
AACR 2021 preview – the early themes emerge
March 24, 2021
Big pharma’s key catalysts in the second quarter
March 03, 2021
A busy year ahead for Parkinson’s disease
March 23, 2021
Frequency refuses to hear the death knell
February 18, 2021
The reckoning begins for biotech-focused Spacs
